There's no sugar-coating it: GlaxoSmithKline (NYSE:GSK) had a pretty rough second quarter. U.S. sales of aging blockbuster Advair dropped by an astounding 19%, and Breo and Anora Ellipta, which have been hailed as potential blockbusters, turned in disappointing sales (5 million pounds each in the U.S.). Watch the video below for a quick take on earnings from Motley Fool health care analysts Michael Douglass and David Williamson.
Leaked: This coming blockbuster will make GlaxoSmithKline jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson owns shares of Novartis. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.